ProMIS Neurosciences Inc.

PMN Nasdaq SEC CIK 1374339
Follow ProMIS Neurosciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$8.2M +29.5% vs same quarter last year
EPS, diluted −$0.89 +85% vs same quarter last year
Operating cash flow −$9.4M +6.7% vs same quarter last year
Operating income −$8.6M +26.7% vs same quarter last year
Net income by quarter
−$238.2K
−$7.3M
−$10.1M
−$11.6M
−$10.7M
−$8.2M
−$11.7M
−$8.2M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income6 fiscal years
−$40M−$20M$0$20MFY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$39.7M
FY24$2.8M
FY23−$13.2M
FY22−$18.1M
FY21−$9.8M
FY20-